Literature DB >> 20206532

Structure-activity relationship of novel DAPK inhibitors identified by structure-based virtual screening.

Masako Okamoto1, Kiyoshi Takayama, Tomoko Shimizu, Ayumu Muroya, Toshio Furuya.   

Abstract

Death-associated protein kinase (DAPK) is a serine/threonine protein kinase implicated in diverse programmed cell death pathways. DAPK is a promising target protein for the treatment of ischemic diseases. We identified novel potent and selective DAPK inhibitors efficiently by structure-based virtual screening, then further developed the hit compounds. In this paper, we describe the development of the hit compounds and the structure-activity relationship studies of the DAPK inhibitors in detail, including calculation of the solvated interaction energy (SIE), and verification of selectivity using a kinase panel. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20206532     DOI: 10.1016/j.bmc.2010.02.018

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  10 in total

1.  Exhaustive search and solvated interaction energy (SIE) for virtual screening and affinity prediction.

Authors:  Traian Sulea; Hervé Hogues; Enrico O Purisima
Journal:  J Comput Aided Mol Des       Date:  2011-12-25       Impact factor: 3.686

2.  Fluorescence linked enzyme chemoproteomic strategy for discovery of a potent and selective DAPK1 and ZIPK inhibitor.

Authors:  David A Carlson; Aaron S Franke; Douglas H Weitzel; Brittany L Speer; Philip F Hughes; Laura Hagerty; Christopher N Fortner; James M Veal; Thomas E Barta; Bartosz J Zieba; Avril V Somlyo; Cindy Sutherland; Jing Ti Deng; Michael P Walsh; Justin A MacDonald; Timothy A J Haystead
Journal:  ACS Chem Biol       Date:  2013-10-17       Impact factor: 5.100

3.  Variability in docking success rates due to dataset preparation.

Authors:  Christopher R Corbeil; Christopher I Williams; Paul Labute
Journal:  J Comput Aided Mol Des       Date:  2012-05-08       Impact factor: 3.686

Review 4.  Opportunities to Target Specific Contractile Abnormalities with Smooth Muscle Protein Kinase Inhibitors.

Authors:  Annegret Ulke-Lemée; Justin A MacDonald
Journal:  Pharmaceuticals (Basel)       Date:  2010-05-26

Review 5.  Death-Associated Protein Kinase 1 as a Promising Drug Target in Cancer and Alzheimer's Disease.

Authors:  Dongmei Chen; Xiao Z Zhou; Tae H Lee
Journal:  Recent Pat Anticancer Drug Discov       Date:  2019       Impact factor: 4.169

6.  Activation of AKT negatively regulates the pro-apoptotic function of death-associated protein kinase 3 (DAPK3) in prostate cancer.

Authors:  Trinath P Das; Suman Suman; A M Sashi Papu John; Deeksha Pal; Angelena Edwards; Houda Alatassi; Murali K Ankem; Chendil Damodaran
Journal:  Cancer Lett       Date:  2016-04-25       Impact factor: 8.679

7.  A novel inhibitory effect of oxazol-5-one compounds on ROCKII signaling in human coronary artery vascular smooth muscle cells.

Authors:  Abdulhameed Al-Ghabkari; Jing-Ti Deng; Paul C McDonald; Shoukat Dedhar; Mana Alshehri; Michael P Walsh; Justin A MacDonald
Journal:  Sci Rep       Date:  2016-08-30       Impact factor: 4.379

Review 8.  Death Associated Protein Kinase 1 (DAPK1): A Regulator of Apoptosis and Autophagy.

Authors:  Pratibha Singh; Palaniyandi Ravanan; Priti Talwar
Journal:  Front Mol Neurosci       Date:  2016-06-23       Impact factor: 5.639

9.  Death-associated protein kinase 1 mediates interleukin-1β production through regulating inlfammasome activation in Bv2 microglial cells and mice.

Authors:  Limin Song; Lei Pei; Lisha Hu; Shangwen Pan; Wei Xiong; Min Liu; Yan Wu; You Shang; Shanglong Yao
Journal:  Sci Rep       Date:  2018-07-02       Impact factor: 4.379

Review 10.  Novel Functions of Death-Associated Protein Kinases through Mitogen-Activated Protein Kinase-Related Signals.

Authors:  Mohamed Elbadawy; Tatsuya Usui; Hideyuki Yamawaki; Kazuaki Sasaki
Journal:  Int J Mol Sci       Date:  2018-10-04       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.